Randomized double-blind controlled study of Qmaitongguan granule intervention on myocardial perfusion after acute myocardial infarction and reperfusion based on myocardial magnetic resonance technology
- Conditions
- Acute myocardial infarction
- Registration Number
- ITMCTR2100004575
- Lead Sponsor
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) With the diagnosis of ST-segment elevation acute myocardial infarction, PCI reperfusion therapy is performed within the time window;
(2) Aged 18-75 years;
(3) Volunteer to participate in this study and have signed an informed consent form;
(4) Have a correct understanding of the significance of drug research, and have a good compliance with the observation and evaluation of researchers.
(1) Patients with severe cardiogenic shock at the time of inclusion;
(2) Patients with suffered cardiac arrest before enrollment and had been undergoing cardiopulmonary resuscitation for a long time;
(3) Patients with cardiac complications such as papillary muscle rupture and ventricular septal perforation;
(4) Aortic dissection patients;
(5) Patients with severe liver, kidney, nerve, and coagulation dysfunction;
(6) Patients with severe infection;
(7) Pregnant or lactating women;
(8) Patients who participated in other Chinese medicine clinical studies within three months;
(9) Those who are allergic to contrast media or the drug components of this study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Myocardial rescue index;Myocardial structure function;
- Secondary Outcome Measures
Name Time Method Seattle Angina Scale Score;NT-pro-BNP;6-minute walk test;TnT;Cystatin C;incidence of MACE;Echocardiography;Quality of Life Scale for Coronary Heart Disease with Integrated Traditional Chinese and Western Medicine and Scale for TCM Syndrome;High sensitivity C-reactive protein;CKMB;